Geriatrics: This indicates that a similar dosage regimen can be used in the elderly, without increasing accumulation of the drug or metabolites.
Pediatrics: No data are available. Fenofibrate is not indicated for use in the pediatric population.
Gender: No pharmacokinetic difference between male and female has been observed for fenofibrate.
Renal insufficiency: The dosage of fenofibrate should be minimized in patients who have severe renal impairment, while no modification of dosage is required in patients having moderate renal impairment.
Hepatic insufficiency: No pharmacokinetic study has been conducted in patients having hepatic insufficiency.
এন্টিকোয়াগুলেন্ট, সাইক্লোপােরিন।
এনোফ্যাব ক্যাপসুল (মাইক্রোনাইজড) সম্পর্কে বিস্তারিত জেনে নিন এই লিঙ্ক থেকে এনোফ্যাব